These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 24567198)

  • 41. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
    Tung NM; Boughey JC; Pierce LJ; Robson ME; Bedrosian I; Dietz JR; Dragun A; Gelpi JB; Hofstatter EW; Isaacs CJ; Jatoi I; Kennedy E; Litton JK; Mayr NA; Qamar RD; Trombetta MG; Harvey BE; Somerfield MR; Zakalik D
    J Clin Oncol; 2020 Jun; 38(18):2080-2106. PubMed ID: 32243226
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
    Drooger J; Akdeniz D; Pignol JP; Koppert LB; McCool D; Seynaeve CM; Hooning MJ; Jager A
    Breast Cancer Res Treat; 2015 Nov; 154(1):171-80. PubMed ID: 26467044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Lynch HT; Ghadirian P; Tung N; Kim-Sing C; Olopade OI; Domchek S; Eisen A; Foulkes WD; Rosen B; Vesprini D; Sun P; Narod SA
    Breast Cancer Res Treat; 2011 May; 127(1):287-96. PubMed ID: 21221768
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prophylactic mastectomy with immediate reconstruction combined with simultaneous laparoscopic salpingo-oophorectomy via a transmammary route: a novel surgical approach to female BRCA-mutation carriers.
    Perabò M; Fink V; Günthner-Biller M; von Bodungen V; Friese K; Dian D
    Arch Gynecol Obstet; 2014 Jun; 289(6):1325-30. PubMed ID: 24389920
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prophylactic surgery in the complex decision-making management of BRCA mutation carriers.
    Briasoulis E; Ziogas D; Fatouros M
    Ann Surg Oncol; 2008 Jun; 15(6):1788-90; author reply 1791-2. PubMed ID: 18197455
    [No Abstract]   [Full Text] [Related]  

  • 46. OncotypeDX© Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis.
    Davey MG; Richard V; Lowery AJ; Kerin MJ
    Eur J Cancer; 2021 Sep; 154():209-216. PubMed ID: 34284256
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
    Cibula D; Zikan M; Dusek L; Majek O
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1197-207. PubMed ID: 21916573
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
    Johns D; Agarwal J; Anderson L; Ying J; Kohlmann W
    J Womens Health (Larchmt); 2017 Jun; 26(6):702-706. PubMed ID: 27922795
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient-Reported Outcome Measures may optimize shared decision-making for cancer risk management in BRCA mutation carriers.
    van Egdom LSE; de Kock MA; Apon I; Mureau MAM; Verhoef C; Hazelzet JA; Koppert LB
    Breast Cancer; 2020 May; 27(3):426-434. PubMed ID: 31832891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differences between screen-detected and interval breast cancers among BRCA mutation carriers.
    Pilewskie M; Zabor EC; Gilbert E; Stempel M; Petruolo O; Mangino D; Robson M; Jochelson MS
    Breast Cancer Res Treat; 2019 May; 175(1):141-148. PubMed ID: 30673971
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
    Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
    J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis.
    Oh M; McBride A; Yun S; Bhattacharjee S; Slack M; Martin JR; Jeter J; Abraham I
    J Natl Cancer Inst; 2018 Nov; 110(11):1178-1189. PubMed ID: 30380096
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer.
    Nilsson MP; Hartman L; Kristoffersson U; Johannsson OT; Borg A; Henriksson K; Lanke E; Olsson H; Loman N
    Breast Cancer Res Treat; 2014 Oct; 147(3):571-8. PubMed ID: 25187270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nipple-Sparing Mastectomy and Its Application on BRCA Gene Mutation Carrier.
    Co M; Chiu R; Chiu TM; Chong YC; Lau S; Lee YH; To HM; Kwong A
    Clin Breast Cancer; 2017 Dec; 17(8):581-584. PubMed ID: 28428099
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
    Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
    Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BRCA1/2 Mutation-associated Breast Cancer, Wide Local Excision and Radiotherapy or Unilateral Mastectomy: A Systematic Review.
    Hallam S; Govindarajulu S; Huckett B; Bahl A
    Clin Oncol (R Coll Radiol); 2015 Sep; 27(9):527-35. PubMed ID: 26113392
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Lynch HT; Klijn J; Ghadirian P; Neuhausen SL; Kim-Sing C; Foulkes WD; Moller P; Isaacs C; Domchek S; Randall S; Offit K; Tung N; Ainsworth P; Gershoni-Baruch R; Eisen A; Daly M; Karlan B; Saal HM; Couch F; Pasini B; Wagner T; Friedman E; Rennert G; Eng C; Weitzel J; Sun P; Narod SA; ; Garber J; Osborne M; Fishman D; McLennan J; McKinnon W; Merajver S; Olsson H; Provencher D; Pasche B; Evans G; Meschino WS; Lemire E; Chudley A; Rayson D; Bellati C
    Breast Cancer Res Treat; 2007 Oct; 105(2):221-8. PubMed ID: 17245541
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.
    Pellegrino B; Bella M; Michiara M; Zanelli P; Naldi N; Porzio R; Bortesi B; Boggiani D; Zanoni D; Camisa R; Neri TM; Pinto C; Musolino A
    Acta Biomed; 2016 May; 87(1):54-63. PubMed ID: 27163896
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas.
    Pierce L
    Semin Radiat Oncol; 2002 Oct; 12(4):352-61. PubMed ID: 12382193
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.
    Heemskerk-Gerritsen BA; Rookus MA; Aalfs CM; Ausems MG; Collée JM; Jansen L; Kets CM; Keymeulen KB; Koppert LB; Meijers-Heijboer HE; Mooij TM; Tollenaar RA; Vasen HF; ; Hooning MJ; Seynaeve C
    Int J Cancer; 2015 Feb; 136(3):668-77. PubMed ID: 24947112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.